甲状腺 Thyroid gland （C73.9）

1 2021 9 1 Thyroid gland ICD-O UICC 8 Ann Arbor 2019 60 10 2017 10 2019 2 2016 10,800 9,800 200 100 Thyroid gland H U left lobe right lobe isthmus 3 5cm pharynx trachea 2 4 17g 15g ICD-O-3 ICD-O , NOS 8 ICD-O-3 Papillary carcinoma 8260/3 Papilliary carcinoma follicular variant 8340/3 Papilliary carcinoma macrofollicular variant 8340/3 Papilliary carcinoma, oxyphilic cell (oncocytic)

2 Variant 8342/3 Papilliary carcinoma diffuse sclerosing variant 8350/3 Papilliary carcinoma tall cell variant 8344/3 Papilliary carcinoma, solid variant 8260/3 Papillary carcinoma cribriform variant 8260/3 Papillary carcinoma, hobnail variant 8260/3 Follicular carcinoma 8330/3 Follicular carcinoma, minimally invasive 8335/3 Follicular carcinoma, encapsulated angioinvasive 8339/3 Follicular carcinoma widely invasive 8330/3 Follicular carcinoma oxyphilic cell variant 8290/3 Follicular carcinoma clear cell variant 8330/3 Poorly differentiated carcinoma 8337/39 Anaplastic carcinoma 8020/3 C Medullary carcinoma (C-cell carcinoma) 8345/3 Mixed mefullary and follicular carcinoma 8346/3 Malignant lymphoma 9590/3 Columnar cell carcinoma 8344/3 Mucinous carcinoma 8480/3 Mucoepidermoid carcinoma 8430/3 Intrathyroid thymic carcinoma ( ittc )

3 8589/3 Spindle cell tumor with thymus-like differentiation (SETTLE) 8588/3 Squamous cell carcinoma 8070/3 , NOS Sarcoma, NOS 8800/3 Immature teratoma of Thyroid 9080/1 TNM UICC 8 2017 T- TX T0 T1 2cm T1a 1cm T1b 1cm 2cm T2 2cm 4cm T3 4cm ( T3a 4cm T3b ( T4a T4b H rthle T1 T3a T T3b N- NX N0 N1 N1a VI))

4 /Delphian N1b VI I II III IV V 2019 12 8 P4 2 I II III IV V Va Vb VI VII VIII IX X XI M- MX M0 M1 Stage- 55 UICC TNM Stage Matrix 55 N0 N1a N1b T IIIM1 IIIIII 55 UICC TNM Stage Matrix 55 N0 N1a N1b T1a,T1b IIIIIT2 IIIIIT3a,T3b IIIIIIT4a IIIIIIIIIT4b IVA IVA IVA M1 IVBIVBIVB UICC TNM Stage Matrix N0 N1a N1b T1a,T1b IIIIIVAT2 IIIIIIVAT3a,T3b IIIIIIVAT4a IVAIVAIVAT4b IVB IVB IVB M1 IVCIVCIVC UICC TNM Stage Matrix N0 N1a N1b T1a,T1b IVAIVBIVBT2 IVAIVBIVBT3a IVAIVBIVBT3b IVBIVBIVBT4a,T4b IVBIVBIVBM1 IVCIVCIVC 2)

5 UICC TNM Matrix N0 N1a N1b T1a,T1b 410 420 420 T2 410 420 420 T3a 410 420 420 T3b 430 430 430 T4a,T4b 430 430 430 M1 440 440 440 1 2 3 CT / MRI RI 131I MIBG CEA Tg Tg Tg Tg Tg 1 1 total thyroidectomy distal pancreatectomy

6 Subtotal thyroidectomy 2/3 hemithyroidectomy isthmectomy enucleation 2 3 2 I131 3 1 Sorafenib, Lenvatinib Va n d e t an i b (Adriamycin, ADM, ) (PTX, ) 2 levothyroxine (T4, S)

7 TSH 4 1 MEN multiple endocrine neoplasia MENIIA Sipple / MENIIB TSH Thyroid -stimulating hormone FNA fine needle aspiration cytology 1) 21 2) 2019 3) 2016 4) 5)Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H and The Japan cancer Surveillanceresearch Group.

8 Cancer incidence and incidence rates in Japan in 2008: A study of 25 population-basedcancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol, 2013;44 )Cogliano VJ, Baan R, Strif K, et al. Preventable exposures associated with human cancers. J Natl CancerInst 2011;103 ) 2010 8) 2019 12 8 9) 10) UICC TNM 8 11) SEER Summary Staging Manual 2000, NIH Publication 01-496912) American Joint of Committee. AJCC Cancer Staging Manual, Sixth F. L. et. al. eds. Springer: Chicago. ) 2 14) 2018 2017 15) 16) 17) 2016